跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 59 条关于
“pyoderma gangrenosum”
全部
59
临床试验
47
药物
1
机构
0
资讯
11
3个月前
OTULIN Mutation Identified as Cause of Pediatric-Onset Pyoderma Gangrenosum, TNF Blockade Shows Therapeutic Promise
8个月前
InflaRx Reports Encouraging Post-Hoc Analyses for Vilobelimab in Pyoderma Gangrenosum Despite Phase 3 Trial Termination
去年
InflaRx Advances Pipeline with Vilobelimab and INF904, Anticipates Key Milestones in 2025
3年前
FDA Grants Emergency Use Authorization for Vilobelimab in Treating Critically Ill COVID-19 Patients
2年前
InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial
8个月前
InflaRx Cuts 30% of Workforce, Deprioritizes COVID-19 Therapy to Focus on Immunology Pipeline
去年
Dermatology Advances: Expanded Clinical Trials and Novel Therapies Reshape Treatment Landscape
去年
InflaRx's Gohibic (vilobelimab) Receives European Commission Approval for SARS-CoV-2-Induced ARDS
去年
InflaRx's Vilobelimab Receives Positive CHMP Opinion for COVID-19-Induced ARDS
6个月前
LEO Pharma Presents Real-World Evidence for Dermatology Portfolio at AAD 2026
第 1 页,共 2 页
上一页
下一页